HPV Vaccination Among Seropositive, DNA Negative Cohorts: a Systematic Review & Meta-analysis

Overview

Journal J Gynecol Oncol

Specialties Gynecology & Obstetrics
Oncology

Date 2022 Feb 7

PMID 35128855

Authors

Colm Mac Eochagain

Robert Power

Imelda Parker

Donal Brennan

Affiliations

Soon will be listed here.

Abstract

Objective: Vaccine efficacy among previously exposed, but currently uninfected women, i.e., those who have serological evidence of a prior human papillomavirus (HPV) infection without corresponding detectable HPV DNA, remains incompletely defined. This meta-analysis assessed the serotype-specific efficacy of prophylactic HPV vaccination against HPV16/18 persistent infection (PI) and cervical intraepithelial neoplasia (CIN) among seropositive, DNA negative (SPDN) women enrolled to randomized controlled trials (RCTs) of HPV L1-based vaccines.

Methods: Searches were conducted on 08/16/20 on MEDLINE, Embase, Scopus and CENTRAL. RCTs of L1-based prophylactic bivalent or quadrivalent HPV vaccines, reporting serotype-specific clinical efficacy endpoints in the HPV16/18 seropositive, DNA-negative populations were included. Relative risks (RRs) of 6-month PI (6mPI), 12-month PI (12mPI), CIN1+ and CIN2+ were pooled using a random-effects model.

Results: A total of 1,727 citations were reviewed. 8 studies, with a total of 9,569 SPDN participants, met all eligibility criteria. The RR of 6mPI (RR=0.22; 95% confidence interval [CI]=0.08-0.61; p=0.018), 12mPI (RR=0.20; 95% CI=0.05-0.80; p=0.035), CIN1+ (RR=0.13; 95% CI=0.05-0.30; p=0.003) and CIN2+ (RR=0.15; 95% CI=0.04-0.59; p=0.022) was significantly reduced in the vaccinated compared to the unvaccinated group.

Conclusion: Our findings suggest high serotype-specific efficacy for HPV vaccination among cohorts of women with evidence of prior HPV16/18 infections, including 87% efficacy (95% CI=70%-95%; p=0.003) against HPV16/18 cervical dysplasia. HPV vaccination is highly effective among uninfected women, regardless of prior exposure history.

Trial Registration: PROSPERO Identifier: CRD42020206888.

Citing Articles

Advancing the Fight Against Cervical Cancer: The Promise of Therapeutic HPV Vaccines.

Zheng Q, He M, Mao Z, Huang Y, Li X, Long L Vaccines (Basel). 2025; 13(1).

PMID: 39852871 PMC: 11768687. DOI: 10.3390/vaccines13010092.

The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20-45 years of age.

Wen T, Xu X, Pan C, Hu S, Zhao H, Zhang X Hum Vaccin Immunother. 2024; 20(1):2412391.

PMID: 39390947 PMC: 11486006. DOI: 10.1080/21645515.2024.2412391.

Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications.

Sausen D, Shechter O, Gallo E, Dahari H, Borenstein R Cancers (Basel). 2023; 15(14).

PMID: 37509353 PMC: 10378257. DOI: 10.3390/cancers15143692.

Updates on HPV Vaccination.

Illah O, Olaitan A Diagnostics (Basel). 2023; 13(2).

PMID: 36673053 PMC: 9857409. DOI: 10.3390/diagnostics13020243.

References

Liu S, Cummings D, Zenilman J, Gravitt P, Brotman R . Characterizing the temporal dynamics of human papillomavirus DNA detectability using short-interval sampling. Cancer Epidemiol Biomarkers Prev. 2013; 23(1):200-8. PMC: 3947138. DOI: 10.1158/1055-9965.EPI-13-0666. View

Moscicki A, Flowers L, Huchko M, Long M, MacLaughlin K, Murphy J . Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. J Low Genit Tract Dis. 2019; 23(2):87-101. DOI: 10.1097/LGT.0000000000000468. View

Schiller J . The Potential Benefits of HPV Vaccination in Previously Infected Women. EBioMedicine. 2016; 10:5-6. PMC: 5006803. DOI: 10.1016/j.ebiom.2016.08.005. View

Scherer E, Smith R, Gallego D, Carter J, Wipf G, Hoyos M . A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects. EBioMedicine. 2016; 10:55-64. PMC: 5006801. DOI: 10.1016/j.ebiom.2016.06.042. View

Malik Z, Hailpern S, Burk R . Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol. 2009; 22(6):445-9. PMC: 2883483. DOI: 10.1089/vim.2009.0055. View

Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E . Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis. 1995; 171(4):1026-30. DOI: 10.1093/infdis/171.4.1026. View

Paternoster D, Cester M, Resente C, Pascoli I, Nanhorngue K, Marchini F . Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc. 2008; 40(6):1877-80. DOI: 10.1016/j.transproceed.2008.05.074. View

Brotman R, Shardell M, Gajer P, Tracy J, Zenilman J, Ravel J . Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis. 2014; 210(11):1723-33. PMC: 4296189. DOI: 10.1093/infdis/jiu330. View

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

10.

Broker T, Jin G, Bragg S, Richardson M, Chow L, Vermund S . Viral latency--the papillomavirus model. Dev Biol (Basel). 2002; 106:443-51; discussion 452-3, 465-75. View

11.

Kelly H, Weiss H, Benavente Y, de Sanjose S, Mayaud P . Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2017; 5(1):e45-e58. PMC: 5757426. DOI: 10.1016/S2352-3018(17)30149-2. View

12.

Palmer T, Wallace L, Pollock K, Cuschieri K, Robertson C, Kavanagh K . Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019; 365:l1161. PMC: 6446188. DOI: 10.1136/bmj.l1161. View

13.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

14.

Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K . End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011; 105(1):28-37. PMC: 3137403. DOI: 10.1038/bjc.2011.185. View

15.

Beachler D, Kreimer A, Schiffman M, Herrero R, Wacholder S, Rodriguez A . Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. J Natl Cancer Inst. 2015; 108(1). PMC: 4862406. DOI: 10.1093/jnci/djv302. View

16.

Strickler H, Burk R, Fazzari M, Anastos K, Minkoff H, Massad L . Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005; 97(8):577-86. DOI: 10.1093/jnci/dji073. View

17.

Maglennon G, McIntosh P, Doorbar J . Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology. 2011; 414(2):153-63. PMC: 3101335. DOI: 10.1016/j.virol.2011.03.019. View

18.

Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

19.

Xi L, Demers G, Koutsky L, Kiviat N, Kuypers J, Watts D . Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis. 1995; 172(3):747-55. DOI: 10.1093/infdis/172.3.747. View

20.

Dehlendorff C, Baandrup L, Kjaer S . Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers. J Natl Cancer Inst. 2020; 113(7):869-874. PMC: 8246827. DOI: 10.1093/jnci/djaa209. View

HPV Vaccination Among Seropositive, DNA Negative Cohorts: a Systematic Review &amp; Meta-analysis

HPV Vaccination Among Seropositive, DNA Negative Cohorts: a Systematic Review & Meta-analysis